<html xmlns:fo="http://www.w3.org/1999/XSL/Format">

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_darunavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
<head>
<META http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>Johns Hopkins POC-IT: Point of Care Information Technology</title>
<meta content="text/html; charset=iso-8859-1" http-equiv="Content-Type">
<link href="../../images/styles.css" type="text/css" rel="stylesheet">
<script type="text/JavaScript" src="../../images/functions.js" language="JavaScript"></script>
</head>
<body>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td>Johns Hopkins POC-IT: Point of Care Information Technology</td><td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td >
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td></td><td>
<table cellspacing="0" cellpadding="0" border="0">
<tr>
<td class="tdVAlignMiddle" align="center" >
                                                            &nbsp;</td>
</tr>
<tr></tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr>
<td  ><span class="mainNav">&nbsp;Print-Friendly Module</span></td>
</tr>
</table>
</td>
</tr>
</table>
<p></p>
<table cellspacing="0" cellpadding="0" border="0" >
<tr>
<td></td><td>
<table >
<tr>
<td><span class="primaryItemTitle"><font size="6">Darunavir</font></span>
<br>
</td><td align="right" valign="top"><a href="javascript:window.print();"></a></td>
</tr>
<tr>
<td colspan="2">
<br>
        Author: <author maxOccurance="1" tag="author" use="required">Paul A. Pham, Pharm.D. and John G. Bartlett, MD</author>
<br>
<span class="display_date">06-17-2008</span>
<br>
<div style="background-color:#ccffcc;">
<a name=""></a>
<h2 class="grayLineHeaderBar"></h2>
<ul>
<li>Currently not available in Zambia. </li>
<li>A twice-daily PI with good efficacy in both treatment-naive and highly treatment-experienced pts. </li>
</ul>Zambia Information Author: Paul A. Pham, Pharm. D. <br>
<br>
</div>
<a name="INDICATIONS"></a>
<h2 class="grayLineHeaderBar">INDICATIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">FDA</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV-infected patients who are treatment-experienced and have virus resistant to <U>&gt;</U>1PI, in combination with other antiretrovirals. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">NON-FDA APPROVED USES</span></td>
</tr>
</table>
<hr>
<ul>
<li>Treatment of HIV infection in ART-naive or PI-naive patients, in combination with other antiretrovirals (under study) </li>
</ul>
<a name="FORMS"></a>
<h2 class="grayLineHeaderBar">FORMS</h2>
<TABLE  class="blueOutline" cellspacing="0" cellpadding="2" border="0">
<TR class="blueBarBG">
<TD><B>brand name</B></TD><TD><B>preparation</B></TD><TD><B>manufacturer</B></TD><TD><B>route</B></TD><TD><B>form</B></TD><TD><B>dosage^</B></TD><TD><B>cost*</B></TD>
</TR>
        
<TR>
<TD valign="top">Prezista</TD><TD valign="top">Darunavir (DRV)</TD><TD valign="top">Tibotec Therapeutics</TD><TD>Oral</TD><TD>tablet</TD><TD>300 mg </TD><TD>$8.56</TD>
</TR>
<TR>
<TD valign="top">&nbsp;            
            </TD><TD valign="top">&nbsp;
            </TD><TD valign="top">&nbsp;                
            </TD><TD>Oral </TD><TD>tablet </TD><TD>600 mg </TD><TD>$17.12 </TD>
</TR>
      
</TABLE>
<p>*Costs (rounded to the nearest dollar) are based on usual adult dosing per day, 
                are representative of "Average Wholesale Price" (AWP), and are current within the prior three months.</p>
<p>^Dosage is indicated in mg unless otherwise noted.</p>
<a name="USUAL ADULT DOSING"></a>
<h2 class="grayLineHeaderBar">USUAL ADULT DOSING</h2>
<ul>
<li>DRV 600 mg (one 600 mg tab) + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg twice-daily &nbsp;with food. In treatment-naive patients: consider DRV 900 (three 300 mg tabs) + <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> 100 mg once-daily with food. Note: ARTEMIS trial used DRV/r 800/100 mg once-daily, but formulation currently not available. </li>
<li>With <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A>: dose not established; consider standard dose of both drugs&nbsp;(limited data)</li>
<li>With <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A>: standard dose DRV/r + <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg once-daily. </li>
<li>With <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A>: standard dose of both drugs&nbsp;(limited data).</li>
<li>Not recommended with <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A>/rand <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A>; dose not established. </li>
<li>With <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>: dose not established</li>
<li>&nbsp;No data with <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>, <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>, and <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>; avoid co-administration.</li>
<li>Wtih <A class="headLines" target="_new" href="enfuvirtide5d38.html?contentInstanceId=443127">ENF</A>: standard dose of both drugs. </li>
<li>With <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">ETR</A>: standard dose of both drugs. </li>
<li>With <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A>: standard dose DRV/r + <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> 150 mg twice-daily </li>
<li>With RAL: standard dose of both drugs. </li>
</ul>
<a name="RENAL DOSING"></a>
<h2 class="grayLineHeaderBar">RENAL DOSING</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 50-80</span></td>
</tr>
</table>
<hr>DRV/r 600/100 mg twice-daily <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF 10-50</span></td>
</tr>
</table>
<hr>DRV/r 600/100 mg twice-daily <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR GLOMERULAR FILTRATION OF &lt;10 ML/MIN</span></td>
</tr>
</table>
<hr>Consider: DRV/r 600/100 mg twice-daily (limited data) <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMODIALYSIS</span></td>
</tr>
</table>
<hr>Consider: DRV/r 600/100 mg twice-daily (limited data) <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN PERITONEAL DIALYSIS</span></td>
</tr>
</table>
<hr>Consider: DRV/r 600/100 mg twice-daily (limited data) <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING IN HEMOFILTRATION</span></td>
</tr>
</table>
<hr>Consider: DRV/r 600/100 mg twice-daily (no data) <br>
<br>
<a name="ADVERSE DRUG REACTIONS"></a>
<h2 class="grayLineHeaderBar">ADVERSE DRUG REACTIONS</h2>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">GENERAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Adverse reactions comparable to comparator PIs in POWER studies. Discontinuation due to AEs: 9% and 5% in the DRV/r and comparator PI arms, respectively. </li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">COMMON</span></td>
</tr>
</table>
<hr>
<ul>
<li>GI intolerance (<A class="headLines" target="_new" href="../../diagnosis/organ_system/nausea_vomiting1649.html?contentInstanceId=432759">nausea, vomiting</A>, and/or <A class="headLines" target="_new" href="../../diagnosis/organ_system/diarrhea8e47.html?contentInstanceId=432753">diarrhea</A>) in 20%.</li>
<li>Headache in 15%.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">OCCASIONAL</span></td>
</tr>
</table>
<hr>
<ul>
<li>Contains sulfonamide moiety and should be used with caution in pts with severe sulfa allergy. </li>
<li>Rash observed in 7% of pts with 0.3% discontinuation rate.</li>
<li>
          
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/lipodystrophy94a9.html?contentInstanceId=432804">Lipodystrophy</A>
        
</li>
<li>
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/diabetes_mellitus_and_insulin_resistance382a.html?contentInstanceId=432783">Insulin resistance</A> and hyperglycemia</li>
<li>
          
<A class="headLines" target="_new" href="../../diagnosis/complications_of_therapy/hyperlipidemia4edb.html?contentInstanceId=434827">Hyperlipidemia</A>
        
</li>
<li>Tansaminase elevation</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">RARE</span></td>
</tr>
</table>
<hr>
<ul>
<li>Severe rash</li>
<li>FDA black box warning: severe hepatitis (reported in 0.5%) </li>
</ul>
<a name="DRUG INTERACTIONS"></a>
<h2 class="grayLineHeaderBar">DRUG INTERACTIONS</h2>
<ul>
<li>Substrate and inhibitor of CYP3A4. With <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration, net effect of DRV/r on CYP3A4 is generally inhibitory. CYP3A4 inhibitors and inducers may increase or decrease DRV serum concentrations, respectively.</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">Drug-to-Drug Interactions</span></td>
</tr>
</table>
<hr>
<a name="Drug-to-Drug Interaction"></a>
<h2 class="grayLineHeaderBar">Drug-to-Drug Interaction</h2>
<TABLE class="blueOutline" CELLPADDING="2" CELLSPACING="0"  BORDER="0">
<tr class="blueBarBG">
<td>Drug</td><td>Effect of Interaction</td><td>Recommendations/Comments</td>
</tr>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">Atazanavir (ATV)</A>
          </B></TD><TD valign="top">No interaction</TD><TD valign="top">Dose: <A class="headLines" target="_new" href="atazanavir766b.html?contentInstanceId=441414">ATV</A> 300 mg once-daily + DRV/r 600/100 mg twice-daily. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">Efavirenz (EFV)</A>
          </B></TD><TD valign="top">DRV Cmin decreased by 31%. <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> AUC and Cmin increased 21% and 17%, respectively.</TD><TD valign="top">Dose not established since initial PK study used only DRV 300/100 mg twice-daily. Consider: DRV/r 600/100 mg twice-daily plus <A class="headLines" target="_new" href="efavirenz9b36.html?contentInstanceId=432942">EFV</A> 600 mg once-daily .</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="enfuvirtide5d38.html?contentInstanceId=443127">Enfuvirtide</A>
          </B></TD><TD valign="top">No interaction</TD><TD valign="top">Use standard dose </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">Indinavir</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC and Cmin increased 23% and 125%, respectively. DRV AUC and Cmin increased 24% and 44%, respectively.</TD><TD valign="top">Dose not established. May increase risk of nephrolithiasis. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tenofovir0121.html?contentInstanceId=439564">Tenofovir (TDF)</A>
          </B></TD><TD valign="top">DRV: no change. TDF AUC and Cmin increased 22% and 37% respectively. </TD><TD valign="top">Use standard dose</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/clarithromycin2448.html?contentInstanceId=434158">Clarithromycin</A>
          </B></TD><TD valign="top">DRV: no change. Clarithromycin AUC increased 57%.</TD><TD valign="top">Dose: adjust clarithromycin dose according to renal function. CrCl 30-60 ml/min=250 mg twice-daily, CrCl&lt;30 ml/min = 250 mg once-daily. Avoid with QTc prolongation. Consider using azithromycin. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="../antimicrobial_agents/rifampicin532e.html?contentInstanceId=434653">Rifampin</A>
          </B></TD><TD valign="top">May significantly decrease DRV serum concentration.</TD><TD valign="top">Avoid co-administration. Consider rifabutin</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">Etravirine</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">Etravirine</A> AUC decreased by 37%.</TD><TD valign="top">Despite drug-drug interaction, good clinical efficacy with DRV/r plus <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">ETR</A> co-administration. No dosage adjustments necessary. <A class="headLines" target="_new" href="etravirine4427.html?contentInstanceId=443125">ETR</A>200 mg twice-daily plus DRV/r 600/100 mg twice-daily.</TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="fosamprenavir551f.html?contentInstanceId=441415">FPV</A>
          </B></TD><TD valign="top">No data </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="nelfinaviraafb.html?contentInstanceId=432948">NFV</A>
          </B></TD><TD valign="top">No data </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>
          </B></TD><TD valign="top">May significantly decrease DRV serum concentrations. </TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="indinavirfd01.html?contentInstanceId=432945">IDV</A> AUC increased 23%. DRV AUC increased 24%. </TD><TD valign="top">Dose not established; avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A>
          </B></TD><TD valign="top"><A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> AUC increased 4-fold. </TD><TD valign="top">Dose: DRV/r 600/100 mg twice-daily plus <A class="headLines" target="_new" href="maraviroc7e32.html?contentInstanceId=443126">MVC</A> 150 mg twice-daily. </TD>
</TR>
<TR>
<TD valign="top"><B>Acid reducing agents (PPIs, H-2 blocker)</B></TD><TD valign="top">No interactions</TD><TD valign="top">Use standard dose</TD>
</TR>
<TR>
<TD valign="top"><B>Amiodarone<BR>
</B></TD><TD valign="top">DRV/r may increase serum concentration of amiodarone.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>Astemizole</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of astemizole.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmia.</TD>
</TR>
<TR>
<TD valign="top"><B>Atorvastatin</B></TD><TD valign="top">Increased atorvastatin exposure by approximately 4-fold. </TD><TD valign="top">Dose: Start with atorvastatin 10 mg once-daily and titrate slowly. Avoid doses &gt;40 mg/d</TD>
</TR>
<TR>
<TD valign="top"><B>Bepridil<BR>
</B></TD><TD valign="top">DRV/r may increase serum concentration of bepridil.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>Calcium channel blockers (felodipine, nifedipine, and nicardipine) <BR>
</B></TD><TD valign="top">DRV/r may increase serum concentration of felodipine, nifedipine, and nicardipine.</TD><TD valign="top">May need to decrease calcium channel blockers dose by 50%. Use with close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>Carbamazepine</B></TD><TD valign="top">May significantly decrease DRV serum concentration.</TD><TD valign="top">Avoid co-administration. Consider valproic acid or levitaracetam.</TD>
</TR>
<TR>
<TD valign="top"><B>Cisapride</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of cisapride.</TD><TD valign="top">Contraindicated due to the potential for cardiac arrhythmia.</TD>
</TR>
<TR>
<TD valign="top"><B>Cyclosporine</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of cyclosporine</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring of cyclosporine serum concentration</TD>
</TR>
<TR>
<TD valign="top"><B>Ergot alkaloid</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of ergot alkaloid.</TD><TD valign="top">Contraindicated due to the potential for acute ergotism.</TD>
</TR>
<TR>
<TD valign="top"><B>Ethinyl estradiol/norethindrone </B></TD><TD valign="top">DRV/r decreased ethinyl estradiol AUC 44%.</TD><TD valign="top">Use with caution. Use an alternative form of contraception.</TD>
</TR>
<TR>
<TD valign="top"><B>Fluticasone</B></TD><TD valign="top">DRV/r may increase serum concentration of fluticasone</TD><TD valign="top">Concurrent use of fluticasone and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> might lead in increased fluticasone plasma concentrations and decreased cortisol, resulting in Cushing's syndrome. Avoid long-term co-administration or use with dose adjustment and close monitoring. Consider beclomethasone.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Itraconazole
          </B></TD><TD valign="top">DRV/r may increase serum concentration of itraconazole.</TD><TD valign="top">Monitor itraconazole serum concentrations.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Ketoconazole
          </B></TD><TD valign="top">DRV AUC increased 42%. Ketoconazole AUC increased 212%.</TD><TD valign="top">Do not exceed ketoconazole 200 mg once-daily or use alternative agent</TD>
</TR>
<TR>
<TD valign="top"><B>Lidocaine<BR>
</B></TD><TD valign="top">DRV/r may increase serum concentration of lidocaine.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>
            Lopinavir (LPV)
          </B></TD><TD valign="top">DRV AUC and Cmin decreased 53% and 65%, respectively. <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> AUC and Cmin increased 37% and 72%, respectively.</TD><TD valign="top">Avoid co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Lovastatin</B></TD><TD valign="top">DRV/r may significantly increase simvastatin serum concentration.</TD><TD valign="top">Avoid co-administration. Consider alternative statin (pravastatin, atorvastatin, and possibly rosuvastatin).</TD>
</TR>
<TR>
<TD valign="top"><B>
            Methadone
          </B></TD><TD valign="top">DRV/r decreasedR-methadone AUC by 16%.</TD><TD valign="top">Monitor for sign and Sx of withdrawal. Titrate methadone dose as needed.</TD>
</TR>
<TR>
<TD valign="top"><B>Midazolam<BR>
</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of midazolam</TD><TD valign="top">Contraindicated due to potential for increased sedation?Consider lorazepam</TD>
</TR>
<TR>
<TD valign="top"><B>
            Nevirapine (NVP)
          </B></TD><TD valign="top">No significant change in DRV AUC and Cmin. <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> AUC and Cmin increased 27% and 47%, respectively.</TD><TD valign="top">Limited data (historical control comparison). Consider: DRV/r 600/100 mg twice-daily plus <A class="headLines" target="_new" href="nevirapinebc24.html?contentInstanceId=432949">NVP</A> 200 mg twice-daily</TD>
</TR>
<TR>
<TD valign="top"><B>Paroxetine</B></TD><TD valign="top">Paroxetine AUC decreased by 39%. DRV: no change</TD><TD valign="top">Titrate paroxetine to therapeutic effect.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenobarbital<BR>
</B></TD><TD valign="top">May significantly decrease DRV serum concentration.</TD><TD valign="top">Avoid co-administration. Consider valproic acid or levitaracetam.</TD>
</TR>
<TR>
<TD valign="top"><B>Phenytoin</B></TD><TD valign="top">May significantly decrease DRV serum concentration.</TD><TD valign="top">Avoid co-administration. Consider valproic acid or levitaracetam.</TD>
</TR>
<TR>
<TD valign="top"><B>Pimozide</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of pimozide.</TD><TD valign="top">Contraindicated due to potential for QTc prolongation.</TD>
</TR>
<TR>
<TD valign="top"><B>Pravastatin</B></TD><TD valign="top">Pravastatin AUC increased 81%</TD><TD valign="top">Dose: Start with 10 mg once-daily  and titrate slowly</TD>
</TR>
<TR>
<TD valign="top"><B>Prednisone</B></TD><TD valign="top">DRV/r may increase serum concentration of prednisone</TD><TD valign="top">Concurrent use of prednisone and <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> might lead in increased prednisone plasma concentrations and decreased cortisol, resulting in Cushing's syndrome. Avoid long-term co-administration or use with dose adjustment and close monitoring. </TD>
</TR>
<TR>
<TD valign="top"><B>Propafenone<BR>
</B></TD><TD valign="top">DRV/r may increase serum concentration of propafenone.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>
            Quinidine
            <BR>
          
</B></TD><TD valign="top">DRV/r may increase serum concentration of quinidine.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>
            RAL
          </B></TD><TD valign="top">Interaction unlikely </TD><TD valign="top">Use standard dose of both drugs. </TD>
</TR>
<TR>
<TD valign="top"><B>Ranolazine </B></TD><TD valign="top">May significantly increase ranolazine serum concentrations. </TD><TD valign="top">Contraindicated. May increase risk of QTc prolongation. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Rifabutin
          </B></TD><TD valign="top">DRV/r may increase serum concentration of rifabutinNo data on DRV PK with co-administration.</TD><TD valign="top">Dose: Consider rifabutin 150 mg every other day with DRV/r co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Saquinavir (SQV)
          </B></TD><TD valign="top">DRV AUC and Cmin decreased 25% and 42%, respectively. No change in <A class="headLines" target="_new" href="saquinavir964d.html?contentInstanceId=432951">SQV</A> serum concentration.</TD><TD valign="top">Avoid co-administration.</TD>
</TR>
<TR>
<TD valign="top"><B>Sertraline</B></TD><TD valign="top">Sertraline AUC decreased by 49%. DRV: no change</TD><TD valign="top">Titrate sertraline to therapeutic effect. </TD>
</TR>
<TR>
<TD valign="top"><B>Sildenafil</B></TD><TD valign="top">No significant change in sildenafil AUC between 25 mg (with DRV/r) and 100 mg (without DRV/r).</TD><TD valign="top">Use with caution. Do not exceed 25 mg in 48h.</TD>
</TR>
<TR>
<TD valign="top"><B>Simvastatin</B></TD><TD valign="top">DRV/r may significantly increase simvastatin serum concentration.</TD><TD valign="top">Avoid co-administration. Consider alternative statin (pravastatin, atorvastatin, and possibly rosuvastatin).</TD>
</TR>
<TR>
<TD valign="top"><B>Sirolimus<BR>
</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of sirolimus.</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring of sirolimus serum concentration.</TD>
</TR>
<TR>
<TD valign="top"><B>St John's wort </B></TD><TD valign="top">May significantly decrease DRV serum concentration.</TD><TD valign="top">Avoid co-administration. </TD>
</TR>
<TR>
<TD valign="top"><B>Tacrolimus<BR>
</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of tacrolimus. </TD><TD valign="top">Avoid or use with dose adjustment and close monitoring of tacrolimus serum concentration.</TD>
</TR>
<TR>
<TD valign="top"><B>tadalafil</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of tadalafil</TD><TD valign="top">Avoid or use with dose adjustment and close monitoring. Dose adjustment: tadalafil 10 mg q72h</TD>
</TR>
<TR>
<TD valign="top"><B>Terfenadine<BR>
</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of terfenadine..</TD><TD valign="top">Contraindicated due to potential for cardiac arrhythmia.</TD>
</TR>
<TR>
<TD valign="top"><B>
            Trazodone
          </B></TD><TD valign="top">DRV/r may increase serum concentration of trazodone.</TD><TD valign="top">Use with dose adjustment and close monitoring</TD>
</TR>
<TR>
<TD valign="top"><B>Triazolam<BR>
</B></TD><TD valign="top">DRV/r may significantly increase serum concentration of triazolam.</TD><TD valign="top">Contraindicated due to potential for increased sedation. Consider lorazepam.</TD>
</TR>
<TR>
<TD valign="top"><B>Vardenafil </B></TD><TD valign="top">DRV/r may significantly increase serum concentration of vardenafil </TD><TD valign="top">Avoid or use with dose adjustment and close monitoring. Use with caution. Dose adjustment: vardenafil 2.5 mg q 72h. </TD>
</TR>
<TR>
<TD valign="top"><B>
            Voriconazole
          </B></TD><TD valign="top">DRV/r may decrease voriconazole serum concentration</TD><TD valign="top">Use with caution. Monitor voriconazole serum concentration (target Cmin &gt;2mcg/mL). </TD>
</TR>
<TR>
<TD valign="top"><B>Warfarin<BR>
<BR>
</B></TD><TD valign="top">DRV/r may decrease warfarin serum concentration</TD><TD valign="top">Use with close INR monitoring</TD>
</TR>
</TABLE>
<a name="RESISTANCE"></a>
<h2 class="grayLineHeaderBar">RESISTANCE</h2>
<ul>
<li>Baseline phenotypic DRV fold-change (FC) was strongest predictor of virologic response in POWER studies. At wk 24, 50%, 25%, and 13% of ptts with FC &lt;10, 10-40, and &gt;40&nbsp;achieved VL &lt;50, respectively. FCs of &lt;10, 10-40, and &gt;40 were associated with &lt;10, 10 or 11, and &gt;12 IAS PI mutations. The following mutations were more predictive of virologic outcome than IAS PI mutations: 11I, 32I, 33F, 47V, 50V, 54L/M, 74P, 76V, 84V, and 89V [De Meyer, et al. XV International HIV Drug Resistance Workshop, 2006, Abstract 73]. With 0-2, 3, or &gt;4 of these mutations at baseline, the virologic response (VL &lt;50 c/mL at Week 24) was 50%, 22%, and 10% respectively. </li>
<li>
<I>In vitro</I>, pathway to DRV resistance is different from other PIs. Among mutations emerging during virologic failure (pts with virologic rebound or never suppressed) in POWER studies, most common substitutions occurred at position V32 (30% of isolates), I54 (20% isolates), and I15, L33, I47, G73, and L89 (10-20% of isolates). In these isolates, median DRV phenotypic FC increased from 21-fold at baseline to 94-fold at failure. </li>
<li>
<I>In vitro</I>, 77% and 70% of clinical isolates (n=2682) that have decreased susceptibility to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> and <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>, respectively, were susceptible (FC&lt;10) to DRV [De Meyer, et al. XV International HIV Drug Resistance Workshop, 2006, Abstract 73]. Using Virco's lower DRV FC cutoff of 3.4, other investigators reported higher cross-resistance rates. Analyses of &gt;50,000 isolates found that only 42% and 28% of isolates with resistance to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> and <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A> will have predicted response to DRV [Staes M, et al. International HIV Drug Resistance Workshop, 2006, Abstract 28 ]. However, cinical isolates (n=586) with decreased susceptibility to DRV retained susceptibility to <A class="headLines" target="_new" href="lopinavir_ritonavir40d3.html?contentInstanceId=432947">LPV</A> and <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A> in only 0.5% and 53% of cases, respectively [De Meyer, et al. XV International HIV Drug Resistance Workshop, 2006, Abstract 73].</li>
<li>Current fold-change cut-offs for DRV susceptibility: Monogram <I>PhenoSense</I> lower clinicial cut-off (LCCO) 10, upper CCO 90; Virco <I>Antivirogram</I> LCCO 10, UCCO 40; Virco <I>VircoTYPE </I>LCCO 10, UCCO 106.9. </li>
</ul>
<a name="PHARMACOLOGY"></a>
<h2 class="grayLineHeaderBar">PHARMACOLOGY</h2>
<a name="N10C62"></a>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">MECHANISM</span></td>
</tr>
</table>
<hr>HIV-protease inhibitor<br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PHARMACOKINETIC PARAMETERS</span></td>
</tr>
</table>
<hr>
<ul>
<li>Absorption: 
                With <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> co-administration, DRV is well absorbed with an absolute bioavailability of 82%. Food (a light snack or a full meal) increases DRV AUC by 30%. </li>
<li>Metabolism and Excretion: 
                DRV undergoes extensive oxidative metabolism via CYP3A4 to weakly active oxidative.</li>
<li>Protein Binding: 
                95% </li>
<li>Cmax, Cmin, and AUC: 
                At steady-state, the geometric mean DRV AUC and Cmin was 62.35 mcg/mL&middot;hr and 3.54 mcg/mL, respectively. DRV trough was 6-fold higher than the EC50 for resistant virus and 18-fold higher than the EC90 for wild type virus. </li>
<li>T1/2: 
                15 hours</li>
</ul>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">DOSING FOR DECREASED HEPATIC FUNCTION</span></td>
</tr>
</table>
<hr>Avoid or use with caution. Severe hepatitis reported in 0.5% of pts treated with DRV/r. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">PREGNANCY RISK</span></td>
</tr>
</table>
<hr>Category B: no human data. DRV has shown no embryotoxicity or teratogenicity in mice, rats and rabbits. Inadequate data to recommend in pregnancy. <br>
<br>
<table  cellspacing="0" cellpadding="0" border="0">
<tr>
<td><span class="header12px">BREAST FEEDING COMPATIBILITY</span></td>
</tr>
</table>
<hr>No data. Not recommended<a name="COMMENTS"></a>
<h2 class="grayLineHeaderBar">COMMENTS</h2>
<ul>
<li>Pros: effective in highly treatment-experienced pts with better safety profile than <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>/r. Superior to LPV/r in LPV/r-naive, treatment-experienced patients (non-inferior in those with baseline LPV susceptibility, but trend toward better outcome with DRV/r, and less virologic failure and emergence of new mutations). </li>
<li>Cons:&nbsp;Requires <A class="headLines" target="_new" href="ritonavir974c.html?contentInstanceId=432950">RTV</A> boosting. PI-class adverse effects. Severe hepatitis reported; as with other PIs, greatest risk in pts with chronic HBV or HCV infection</li>
</ul>
<a name="N10CAF"></a><a name="References"></a>
<h2 class="grayLineHeaderBar">References</h2>
<ol>
<li>DeJesus E, Ortiz R, Khanlou H, et al. ;
		Efficacy and safety of darunavir/ritonavir versus lopinavir/ritonavir in ARV treatment-naive HIV-1-infected patients at week 48: ARTEMIS (TMC114-C211) ;        
		ICAAC 47th Interscience Conference on Antimicrobial Agents and Chemotherapy Sept 17-20, 2007 Chicago, ILL. ;
		2007 ; Vol. 
		<br>Rating:
			Important <br>
<b>Comments:</b>ARTEMIS evaluated DRV/r (800/100 mg once-daily) vs LPV/r (once- or twice-daily, but majority received twice-daily dosing) both combined with TDF/FTC in treatment-naive pts. Characteristics of pts (n=689) comparable at baseline with a median VL of approx. 70,000 and CD4 220. At 48 wk (ITT-TLOVR), 84% of DRV/r treated pts and 78% of LPV/r-treated pts achieved VL &lt;50,  difference was 5.6% (p&lt;0.0001) and within12% margin of non-inferiority, but missed the claim of superiority (p=0.062). However, in pts with baseline VL &gt;100,000 c/mL, DRV/r was superior (79% vs 67%; P&lt;0.05), which was subsequently attributed to use of once-daily LPV/r. Median CD4 increase comparable between 2 groups (137 for DRV/r and 141 for LPV/r). GI intolerance significantly higher in the LPV/r-treated pts (14% vs. 7%). <br>
<br>
</li>
<li>Madruga JV, Berger D, McMurchie M, et al. ;
		Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. ;        
		Lancet ;
		2007 ; Vol. 
		370 ; pp. 
		49-58 ;
		<br>ISSN:
	        	17617272 ;
	        <br>Rating:
			Important <br>
<b>Comments:</b>Titan trial evaluated DRV/r (600/100 mg q12h) vs. LPV/r (400/100 mg q12h) both with OBT in pts who had failed prior therapy and were naive to LPV/r. Baseline pts characteristic (n=595) comparable between 2 groups: median VL 4.31 log, CD4 232, 31% were PI-naive; 82% were susceptible to 4 or more PIs. At week 48, significantly more DRV/r- than LPV/r-treated pts had VL&lt; 400 c/mL (77% vs 68%; estimated difference 9%, 95% CI 2-16) and within 12% margin of non-inferiority. <br>
<br>
</li>
<li>Clotet B, Bellos N, Molina JM, et al. &nbsp;;
		Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.&nbsp;;        
		&nbsp;Lancet. 2007 Apr 7;369(9568):1169-78.;
		2007; Vol. 
		369 ; pp. 
		1169 ;
		<br>PUBMED: <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17416261&amp;dopt=abstract" target="_new">17416261 </a>
<br>Rating:
			Important <br>
<b>Comments:</b>POWER 1 and 2 demonstrated high rates of virologic suppression in highly treatment-experienced pts treated with DRV/r. All were 3-class (NRTI, NNRTI, PI) experienced and had <U>&gt;</U>1 primary PI mutation at screening. Baseline characteristics (n=131)&nbsp;of pts on DRV/r + OBR were: VL= 4.52 log<SUB>10</SUB>, CD4 153, 8 IAS PI mutations associated with resistance ( &gt;3 primary mutations in 54%), and phenotypic resistance to all approved PIs (with exception of <A class="headLines" target="_new" href="tipranavir9ea2.html?contentInstanceId=443122">TPV</A>/r due to availability) in 64% of pts. After&nbsp;initial dose-finding phase, pts randomized to receive an OBR (<U>&gt;</U>2 NRTIs +/- <A class="headLines" target="_new" href="enfuvirtide5d38.html?contentInstanceId=443127">ENF</A>&nbsp;with DRV/r 600/100 mg twice-daily OR investigator choice of PIs, including boosted or dual-boosted PIs (control group). Primary efficacy endpoint defined as decrease in VL &gt; 1 log vs baseline. By ITT analysis, 61% of DRV/r-treated pts and 15% of control pts achieved <U>&gt;</U>1 log reduction in VL though wk 48. VL&lt;50achieved in 45% and 10% of DRV/r and control pts, respectively (p&lt;0.0001). Mean CD4 increase was 102 and 19 in DRV/r treated pts and control pts, respectively. Adverse drug reactions were comparable between the two groups.<br>
<br>
</li>
</ol>
<br>
</td>
</tr>
</table>
</td><td></td>
</tr>
</table>
<p></p>
<table cellpadding="0" cellspacing="0" border="0" >
<tr>
<td bgcolor="#003366"></td><td class="bottomNav" bgcolor="#003366" >
<center>
<span class="copyrightFullModule">Copyright 2000-2008 Johns Hopkins University.  All rights reserved.</span>
</center>
</td>
</tr>
</table>
</body>

<!-- Mirrored from www.zambiahivguide.org/drugs/antiretrovirals/full_darunavir.html by HTTrack Website Copier/3.x [XR&CO'2007], Thu, 19 Jun 2008 21:24:50 GMT -->
</html>
